Newsroom | 12514 results
Sorted by: Latest
-
European Radiosurgery Center Munich Surpasses 1,000 Patients Treated with ZAP-X Gyroscopic Radiosurgery
SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced that the European Radiosurgery Center Munich (ERCM) has treated more than 1,000 patients with the ZAP-X® Gyroscopic Radiosurgery® platform. The milestone reflects ERCM’s continued leadership in stereotactic radiosurgery (SRS), a completely non-invasive and painless procedure used to treat many primary and metastatic brain tumors, as well as select disorders of...
-
Cosm Medical Announces Licensing and Collaboration Agreement to Advance Post-Surgical Pelvic Recovery with Personalized Gynethotics™ Devices
TORONTO--(BUSINESS WIRE)--Cosm Medical has signed a licensing and collaboration agreement with two leading academic medical centers to develop personalized intravaginal devices...
-
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies receives notice of allowance for Mexican patent on methods of predicting the likelihood of lung cancer using flow cytometry....
-
MedTech Innovator Unveils 65 Startups in its 2026 Accelerator Cohort and Launches the MTI Index, the Definitive Recognition Platform for MedTech Innovation
LOS ANGELES--(BUSINESS WIRE)--MedTech Innovator names 65 startups to 2026 cohort (top 4% of 1,835 applicants) and launches the MTI Index, a quantifiable benchmark for medtech....
-
Stryker bringt das Pangea-Plattensystem auf den Markt und schließt den ersten Eingriff in Europa ab
AMSTERDAM--(BUSINESS WIRE)--Stryker (NYSE:SYK), ein weltweit führendes Unternehmen im Bereich Medizintechnik, gab heute die Markteinführung seines Pangea-Plattensystems in Europa bekannt, einer Plattensystem-Plattform zur Behandlung einer Vielzahl von Frakturmustern. Prof. Alex Trompeter, Design-Chirurg und orthopädischer Unfallchirurg, hat zusammen mit seinem Team am St. George’s University Hospital in London den ersten klinischen Eingriff in Europa durchgeführt. „Pangea wurde mit einem klaren...
-
Stryker lanceert Pangea Plating System en voltooit de eerste case in Europa
AMSTERDAM--(BUSINESS WIRE)--Stryker (NYSE:SYK), een wereldleider in medische technologieën, kondigde vandaag de Europese lancering aan van zijn Pangea Plating System, een platform voor plaatjesosteosynthese voor de behandeling van uiteenlopende breukpatronen. Prof. Alex Trompeter, chirurg-ontwerper en orthopedisch traumachirurg, voltooide de eerste klinische case in Europa samen met zijn team aan de St. George's University Hospital in Londen. “Pangea werd ontwikkeld met een duidelijk doel voor...
-
DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSIS
RAYNHAM, Mass.--(BUSINESS WIRE)--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced an exclusive distribution agreement1 with CGBIO, a biotechnology company specializing in regenerative medicine, for the development and commercialization of NOVOSIS, an advanced bone graft substitute containing growth factors, across its orthopaedic portfolio including spine, craniomaxillofacial (CMF), and trauma. NOVOSIS is a novel growth-factor bone graft substitute desig...
-
Stryker Launches Pangea Plating System and Completes First Case in Europe
AMSTERDAM--(BUSINESS WIRE)--Stryker announced the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns....
-
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
WILMINGTON, Del.--(BUSINESS WIRE)--May 22, 2026 — AstraZeneca and Daiichi Sankyo’s DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval follows Priority Review by the Food and Drug Administration (FDA) based on results from the TROPION-Breast02 Phase III trial which were presented at the 2025 European Societ...
-
Butterfly Network to Participate in the William Blair 46th Annual Growth Stock Conference
NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), today announced that the company will participate at the William Blair 46th Annual Growth Stock Conference. Joseph DeVivo, President, Chief Executive Officer & Chairman and John Doherty, EVP, Chief Financial Officer will participate in a presentation breakout session at 8:40 AM CT on June 4, 2026, and host one-on-one investor meetings throughout the day. A webcast of the presentation will be a...
